Nerveda-backed RetroSense Therapeutics has raised money from investors including Santen Pharmaceutical, and will put the cash towards clinical studies.
US-based biopharmaceutical startup RetroSense Therapeutics raised $6m yesterday in a series B round backed by investors including pharmaceutical company Santen Pharmaceutical.
The round also featured angel network BlueWater Angels, venture capital fund RBV Capital and VC firm ExSight Capital.
RetroSense plans to use the cash to complete a phase 1/2 clinical study for its lead compound, RST-001, which is being developed to treat eye disease retinitis pigmentosa, and to help develop another gene therapy drug candidate.
The round follows a…
